Primary myelofibrosis
Information
- Disease name
- Primary myelofibrosis
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04551066 | Active, not recruiting | Phase 3 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | May 27, 2021 | July 31, 2024 |
| NCT04551053 | Active, not recruiting | Phase 3 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | May 26, 2021 | July 31, 2024 |
| NCT01644110 | Active, not recruiting | Phase 1/Phase 2 | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF | August 2013 | April 2026 |
| NCT03952039 | Active, not recruiting | Phase 3 | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | September 16, 2019 | June 23, 2025 |
| NCT03627403 | Active, not recruiting | Phase 2 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | May 10, 2019 | March 14, 2025 |
| NCT04446650 | Active, not recruiting | Phase 1/Phase 2 | A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | October 12, 2020 | June 30, 2025 |
| NCT04339101 | Active, not recruiting | Phase 2 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | November 11, 2020 | May 22, 2024 |
| NCT05223920 | Active, not recruiting | Phase 2 | Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | December 16, 2021 | August 22, 2024 |
| NCT04603495 | Active, not recruiting | Phase 3 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | April 9, 2021 | December 2027 |
| NCT00095784 | Active, not recruiting | Phase 2 | Decitabine in Treating Patients With Myelofibrosis | September 29, 2004 | February 22, 2025 |
| NCT02158858 | Active, not recruiting | Phase 1/Phase 2 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | July 16, 2014 | October 31, 2024 |
| NCT02251821 | Active, not recruiting | Phase 2 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | October 20, 2014 | December 28, 2025 |
| NCT02370329 | Active, not recruiting | Phase 2 | P1101 in Treating Patients With Myelofibrosis | August 12, 2015 | August 2024 |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00445744 | Completed | N/A | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome | December 2006 | June 2013 |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00795769 | Completed | Phase 2 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | August 8, 2008 | June 10, 2009 |
| NCT00799461 | Completed | Phase 3 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | August 2008 | |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00890747 | Completed | Phase 1 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | August 2009 | |
| NCT00935987 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | November 2009 | April 2012 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01134120 | Completed | Phase 1 | A Study in Myeloproliferative Disorders | April 2010 | February 22, 2018 |
| NCT01178281 | Completed | Phase 3 | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence | September 8, 2010 | May 15, 2018 |
| NCT01199562 | Completed | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | December 2010 | December 2013 | |
| NCT01233921 | Completed | N/A | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | September 2010 | |
| NCT01236638 | Completed | Phase 2 | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | November 2010 | June 2014 |
| NCT01273766 | Completed | Phase 2 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | January 2011 | December 2014 |
| NCT00015821 | Completed | Phase 2 | Thalidomide in Treating Patients With Myelofibrosis | May 2000 | |
| NCT05044026 | Completed | A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis | September 20, 2012 | September 19, 2022 | |
| NCT01371617 | Completed | Phase 2 | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis | October 2011 | August 2012 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01387763 | Completed | Phase 3 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms | January 2012 | June 2020 |
| NCT01423058 | Completed | Phase 1/Phase 2 | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis | August 2011 | June 2014 |
| NCT01423851 | Completed | Phase 1/Phase 2 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | June 2011 | April 22, 2020 |
| NCT01428635 | Completed | Phase 2/Phase 3 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | January 13, 2012 | January 3, 2022 |
| NCT01445769 | Completed | Phase 2 | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis | September 2011 | April 2013 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT04884191 | Completed | Phase 2 | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib | July 31, 2017 | September 4, 2019 |
| NCT01588015 | Completed | Phase 1 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | October 29, 2012 | February 2, 2024 |
| NCT00025415 | Completed | Phase 1 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | August 2001 | |
| NCT01731951 | Completed | Phase 2 | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | October 29, 2012 | May 24, 2018 |
| NCT01732445 | Completed | Phase 2 | Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis | April 2013 | August 10, 2017 |
| NCT00039416 | Completed | Phase 2 | Imatinib Mesylate in Treating Patients With Myelofibrosis | April 2002 | |
| NCT01787552 | Completed | Phase 1/Phase 2 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF | May 8, 2013 | April 10, 2018 |
| NCT01831635 | Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study | April 2013 | June 2015 | |
| NCT01969838 | Completed | Phase 3 | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | December 6, 2013 | May 2, 2019 |
| NCT01981850 | Completed | Phase 2 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | October 1, 2013 | July 10, 2020 |
| NCT02098161 | Completed | Phase 2 | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | December 18, 2014 | May 19, 2022 |
| NCT02124746 | Completed | Phase 2 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | April 30, 2014 | December 6, 2018 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT02311569 | Completed | Phase 2 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | April 2015 | December 2016 |
| NCT03426969 | Completed | Early Phase 1 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | January 31, 2018 | September 21, 2020 |
| NCT02917096 | Completed | Phase 1 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | November 13, 2016 | August 31, 2023 |
| NCT02966353 | Completed | Phase 2 | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. | March 31, 2017 | February 15, 2019 |
| NCT03018223 | Completed | Phase 1 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | January 31, 2017 | March 18, 2021 |
| NCT03065400 | Completed | Phase 2 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms | June 14, 2017 | May 28, 2020 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT03194542 | Completed | Phase 2 | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | November 15, 2017 | July 18, 2022 |
| NCT00227591 | Completed | Phase 2 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | December 2005 | December 2010 |
| NCT00351975 | Completed | Phase 1 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | June 2006 | March 2013 |
| NCT00357305 | Completed | Phase 1 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | May 2006 | |
| NCT00381550 | Completed | Phase 2 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | August 2006 | March 2011 |
| NCT06371573 | Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | April 20, 2017 | March 20, 2024 | |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT03895112 | Completed | Phase 1 | MPN-RC 118 AVID200 in Myelofibrosis | February 15, 2019 | May 16, 2022 |
| NCT03755518 | Completed | Phase 3 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | March 27, 2019 | November 8, 2023 |
| NCT00089011 | Completed | Phase 2 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer | April 2004 | July 2018 |
| NCT02806375 | Completed | Phase 1/Phase 2 | PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis | January 2016 | April 2019 |
| NCT00047190 | Completed | Phase 2 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | August 2002 | |
| NCT04243122 | Completed | Phase 2 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients | February 17, 2021 | May 3, 2024 |
| NCT04173494 | Completed | Phase 3 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | February 7, 2020 | December 29, 2022 |
| NCT05582083 | No longer available | Managed Access Program for Momelotinib in Myelofibrosis | |||
| NCT06047886 | Not yet recruiting | Phase 1 | CD34 Selection Using the Automated CliniMACS Prodigy | June 2024 | December 2029 |
| NCT06343805 | Not yet recruiting | Phase 1 | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | July 15, 2024 | February 15, 2027 |
| NCT06327100 | Not yet recruiting | Phase 2 | Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) | September 30, 2024 | May 1, 2031 |
| NCT05280509 | Recruiting | Phase 1/Phase 2 | Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | June 9, 2022 | April 2027 |
| NCT01688011 | Recruiting | Connect® Myeloid Disease Registry | December 12, 2013 | March 31, 2031 | |
| NCT01787487 | Recruiting | Phase 2 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | March 13, 2013 | April 30, 2025 |
| NCT02386800 | Recruiting | Phase 4 | CINC424A2X01B Rollover Protocol | March 5, 2015 | September 16, 2027 |
| NCT02760238 | Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry | April 2016 | October 2025 | |
| NCT02897297 | Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest | September 2015 | September 2025 | |
| NCT03165734 | Recruiting | Phase 3 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | June 26, 2017 | December 31, 2025 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT04370301 | Recruiting | Phase 2 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | February 9, 2021 | August 31, 2029 |
| NCT04384692 | Recruiting | Phase 2 | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis | December 18, 2020 | December 31, 2029 |
| NCT04517851 | Recruiting | Phase 2 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | February 10, 2021 | December 31, 2024 |
| NCT04640532 | Recruiting | Phase 1/Phase 2 | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | November 17, 2020 | July 24, 2025 |
| NCT04717414 | Recruiting | Phase 3 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | February 25, 2021 | August 23, 2025 |
| NCT05320198 | Recruiting | Phase 1/Phase 2 | Study of DISC-0974 in Participants With Myelofibrosis and Anemia | June 6, 2022 | October 2024 |
| NCT05364762 | Recruiting | Phase 2 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | November 23, 2022 | April 28, 2024 |
| NCT05393674 | Recruiting | Phase 2 | Fedratinib in Combination With Nivolumab | June 14, 2022 | June 30, 2026 |
| NCT05467800 | Recruiting | Phase 2 | Study of Canakinumab in Patients With Myelofibrosis | August 2, 2022 | December 2024 |
| NCT05882773 | Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry | May 2023 | December 2026 | |
| NCT05883904 | Recruiting | Real World Evidence of Fedratinib Effectiveness in MF | January 29, 2024 | January 2026 | |
| NCT06073847 | Recruiting | A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis | July 13, 2023 | December 20, 2027 | |
| NCT06151119 | Recruiting | 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. | November 22, 2023 | June 30, 2025 | |
| NCT06218628 | Recruiting | Phase 1 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | April 5, 2024 | August 27, 2030 |
| NCT06351631 | Recruiting | Phase 3 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | May 23, 2024 | December 4, 2034 |
| NCT06361641 | Recruiting | N/A | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | May 29, 2024 | October 19, 2027 |
| NCT00387426 | Terminated | Phase 2 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | September 2006 | February 2009 |
| NCT01014546 | Terminated | Phase 1 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | April 2010 | February 2015 |
| NCT01159067 | Terminated | Phase 2 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | July 2010 | August 9, 2011 |
| NCT04854096 | Terminated | Phase 2 | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis | January 31, 2023 | May 16, 2024 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT03303950 | Terminated | Phase 2 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | March 30, 2018 | February 19, 2020 |
| NCT03373877 | Terminated | Phase 1 | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis | May 24, 2018 | March 10, 2020 |
| NCT02728700 | Terminated | Phase 1 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | February 2016 | July 2018 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT02421354 | Terminated | Phase 2 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | May 14, 2015 | April 13, 2018 |
| NCT01291784 | Terminated | Phase 1 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | February 2011 | January 2013 |
| NCT02091752 | Terminated | Phase 2 | A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) | September 2014 | February 2015 |
| NCT00722254 | Terminated | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder | June 2006 | February 2009 | |
| NCT02055781 | Terminated | Phase 3 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | February 2014 | April 2016 |
| NCT01790295 | Terminated | Phase 2 | Ruxolitinib Prior to Transplant in Patients With Myelofibrosis | November 2013 | October 26, 2017 |
| NCT01773187 | Terminated | Phase 3 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | January 2013 | April 2016 |
| NCT00931762 | Terminated | Phase 2 | A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis | August 31, 2009 | August 29, 2011 |
| NCT01816022 | Unknown status | Myeloproliferative Neoplasms and Bone Structure | March 2012 | March 2015 | |
| NCT01331603 | Unknown status | Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis | March 2011 | January 2013 | |
| NCT01298934 | Unknown status | Phase 1/Phase 2 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis | September 2009 | July 2015 |
| NCT02530619 | Unknown status | N/A | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia | October 9, 2015 | May 2022 |
| NCT02528877 | Withdrawn | Phase 1 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | November 2015 | |
| NCT04283526 | Withdrawn | Phase 1 | Study of Select Combinations in Adults With Myelofibrosis | November 30, 2020 | April 11, 2024 |
| NCT01558778 | Withdrawn | N/A | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant | May 2012 | |
| NCT04896112 | Withdrawn | Phase 1 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia | April 8, 2021 | October 20, 2022 |
| NCT02584777 | Withdrawn | Phase 2 | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis | November 30, 2015 | August 31, 2020 |
| NCT04054245 | Withdrawn | Phase 2 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | July 24, 2019 | July 24, 2019 |
| NCT02871323 | Withdrawn | Phase 1 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | November 2016 | |
| NCT02805868 | Withdrawn | Early Phase 1 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis | June 2016 |
- OrphaNumber from OrphaNet (Orphanet)
- 824
- MeSH unique ID (MeSH (Medical Subject Headings))
- D055728